Epstein Secrets

cal need to reduce the 45% failure rate of coronary artery by-pass grafts. This is a major unmet medical need in both Russia and the United States. Russian Venture Capital has agreed to provide approximately half of the capital ($3.0M) to launch MALI in its Series A Round. I need to find the matching approximate $3.5M.

opment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. EFTA00351823 OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to

cal need to reduce the 45% failure rate of coronary artery by-pass grafts. This is a major unmet medical need in both Russia and the United States. Russian Venture Capital has agreed to provide approximately half of the capital ($3.0M) to launch MAJI in its Series A Round. I need to find the matching approximate $3.5M.

opment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to risk and retur

cal need to reduce the 45% failure rate of coronary artery by-pass grafts. This is a major unmet medical need in both Russia and the United States. Russian Venture Capital has agreed to provide approximately half of the capital ($3.0M) to launch MAJI in its Series A Round. I need to find the matching approximate $3.5M.

pment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to risk and retur